Standout Papers

The diagnosis and management of nonal... 2003 2026 2010 2018 4.9k
  1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2017)
    Naga Chalasani, Zobair M. Younossi et al. Hepatology
  2. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012)
    Naga Chalasani, Zobair M. Younossi et al. Hepatology
  3. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role ofPGC1andNRF1 (2003)
    Mary‐Elizabeth Patti, Atul J. Butte et al. Proceedings of the National Academy of Sciences
  4. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (2012)
    Naga Chalasani, Zobair M. Younossi et al. Gastroenterology
  5. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis (2006)
    Renata Belfort, Stephen A. Harrison et al. New England Journal of Medicine
  6. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis (2020)
    Philip N. Newsome, Kristine Buchholtz et al. New England Journal of Medicine
  7. Insulin resistance differentially affects the PI 3-kinase– and MAP kinase–mediated signaling in human muscle (2000)
    Kenneth Cusi, Katsumi Maezono et al. Journal of Clinical Investigation
  8. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus (2016)
    Kenneth Cusi, Beverly Orsak et al. Annals of Internal Medicine
  9. Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications (2012)
    Kenneth Cusi Gastroenterology
  10. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies (2018)
    Norbert Stefan, Hans‐Ulrich Häring et al. The Lancet Diabetes & Endocrinology
  11. Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients (2002)
    Yoshinori Miyazaki, Archana Mahankali et al. The Journal of Clinical Endocrinology & Metabolism
  12. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings (2022)
    Kenneth Cusi, Scott Isaacs et al. Endocrine Practice
  13. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012)
    Naga Chalasani, Zobair M. Younossi et al. The American Journal of Gastroenterology
  14. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease (2018)
    Reenam S. Khan, Fernando Bril et al. Hepatology
  15. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels (2015)
    Paola Portillo-Sánchez, Fernando Bril et al. The Journal of Clinical Endocrinology & Metabolism
  16. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease (2021)
    Fasiha Kanwal, Jay H. Shubrook et al. Gastroenterology
  17. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial (2022)
    Amalia Gastaldelli, Kenneth Cusi et al. The Lancet Diabetes & Endocrinology
  18. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options (2019)
    Amalia Gastaldelli, Kenneth Cusi JHEP Reports
  19. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial (2021)
    Samer Gawrieh, Mazen Noureddin et al. Hepatology
  20. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial (2019)
    Fernando Bril, Diane Biernacki et al. Diabetes Care
  21. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening (2020)
    Romina Lomonaco, Eddison Godinez Leiva et al. Diabetes Care
  22. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors (2020)
    Sven Francque, Gyöngyi Szabó et al. Nature Reviews Gastroenterology & Hepatology
  23. Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care (2024)
    Juan Patricio Nogueira, Kenneth Cusi Diabetes Spectrum
  24. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance (2024)
    Vincent Chen, Timothy R. Morgan et al. Hepatology
  25. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD (2025)
    Diana Barb, Srilaxmi Kalavalapalli et al. Journal of Hepatology
  26. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association (2025)
    Kenneth Cusi, Manal F. Abdelmalek et al. Diabetes Care

Immediate Impact

2 by Nobel laureates 12 from Science/Nature 187 standout
Sub-graph 1 of 14

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
113 intermediate papers

Works of Kenneth Cusi being referenced

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
2020 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
and 71 more

Author Peers

Author Last Decade Papers Cites
Kenneth Cusi 22938 14358 8273 213 31.9k
Elisabetta Bugianesi 26731 12431 5249 282 31.7k
Arthur J. McCullough 27432 11652 5439 292 34.4k
Brent A. Neuschwander‐Tetri 24212 10995 5446 186 29.7k
Ariel E. Feldstein 16818 6567 9007 218 26.3k
Joel E. Lavine 23582 11524 3370 144 27.6k
Christopher P. Day 22363 9677 4024 183 30.3k
Naga Chalasani 25932 9759 3998 485 35.8k
Quentin M. Anstee 18861 7626 3875 247 22.8k
Geoffrey C. Farrell 19440 6780 4609 213 25.5k
Mary E. Rinella 17635 7399 3819 127 20.4k

All Works

Loading papers...

Rankless by CCL
2026